ES2104686T3 - Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia. - Google Patents

Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.

Info

Publication number
ES2104686T3
ES2104686T3 ES91890075T ES91890075T ES2104686T3 ES 2104686 T3 ES2104686 T3 ES 2104686T3 ES 91890075 T ES91890075 T ES 91890075T ES 91890075 T ES91890075 T ES 91890075T ES 2104686 T3 ES2104686 T3 ES 2104686T3
Authority
ES
Spain
Prior art keywords
dementia
prophylaxis
peptides
mixture
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91890075T
Other languages
English (en)
Inventor
Yutaka Tsurusawa
Makito Nishiyama
Michitaro Fujimoto
Nobuyuki Iwamoto
Hirokazu Seki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ebewe Pharma GmbH Nfg KG
Original Assignee
Ebewe Pharma GmbH Nfg KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2097207A external-priority patent/JPH03294233A/ja
Priority claimed from JP2206249A external-priority patent/JPH0491034A/ja
Application filed by Ebewe Pharma GmbH Nfg KG filed Critical Ebewe Pharma GmbH Nfg KG
Application granted granted Critical
Publication of ES2104686T3 publication Critical patent/ES2104686T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO DE REALZAR LA PRODUCCION DE NEUROAXONA UTILIZA UNA SOLUCION ACUOSA DE LA MEZCLA DE PEPTIDOS TENIENDO UN PESO MOLECULAR DE 10.000 O MENOS, OBTENIDO POR LA DESCOMPOSICION ENZIMATICA DE PROTEINAS Y AMINO ACIDOS COMO INGREDIENTES ACTIVOS. UN MEDICAMENTO CORRESPONDIENTE PUEDE SER UTIL EN LA PROFILAXIS DE DEMENCIA EN LOS MAMIFEROS.
ES91890075T 1990-04-12 1991-04-11 Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia. Expired - Lifetime ES2104686T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2097207A JPH03294233A (ja) 1990-04-12 1990-04-12 神経突起生成を促す方法ならびに神経突起生成剤
JP2206249A JPH0491034A (ja) 1990-08-02 1990-08-02 中枢神経保護剤

Publications (1)

Publication Number Publication Date
ES2104686T3 true ES2104686T3 (es) 1997-10-16

Family

ID=26438396

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91890075T Expired - Lifetime ES2104686T3 (es) 1990-04-12 1991-04-11 Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.

Country Status (4)

Country Link
EP (1) EP0452299B1 (es)
AT (1) ATE154608T1 (es)
DE (1) DE69126563T2 (es)
ES (1) ES2104686T3 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087940C (zh) * 1994-04-26 2002-07-24 中国药品生物制品标准化研究中心 脑蛋白水解物
AU735687B2 (en) * 1997-07-28 2001-07-12 Riken Agent for protecting central nerve cells and enhancing survival thereof
MXPA06003663A (es) * 2003-10-03 2006-06-05 Pharmacia Corp Composiciones de un inhibidor selectivo de la ciclooxigenasa - 2 administrado en condiciones hipotermicas para el tratamiento de trastornos o lesion del sistema nervioso central mediados por isquemicos.
JP2007510756A (ja) * 2003-11-12 2007-04-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 中枢神経系介在障害を治療するためのシクロオキシゲナーゼ−２選択的阻害剤及び神経栄養因子調節剤の組成物
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
EP3449931B1 (en) 2017-08-28 2019-10-16 EVER Neuro Pharma GmbH Use of cerebrolysin
PL4114843T3 (pl) 2020-07-13 2024-02-12 Ever Neuro Pharma Gmbh Sposób wytwarzania hydrolizatu białek mózgu ssaka

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1095464B (de) * 1956-05-22 1960-12-22 Univ Tulane Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten
IL71440A0 (en) * 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
IT1219839B (it) * 1988-02-08 1990-05-24 Fidia Farmaceutici Purificazione,caratterizazione e applicazione di un fattore neuronotrofico derivato da cervello di nammifero
EP0326075B1 (en) * 1988-01-25 1993-09-22 American Cyanamid Company Heparin-binding brain mitogens

Also Published As

Publication number Publication date
EP0452299B1 (en) 1997-06-18
DE69126563D1 (de) 1997-07-24
ATE154608T1 (de) 1997-07-15
DE69126563T2 (de) 1998-02-05
EP0452299A1 (en) 1991-10-16

Similar Documents

Publication Publication Date Title
AU6701890A (en) Process for the production of biologically active protein
ES2056963T3 (es) Agentes antibacterianos.
LV5738B4 (lv) Aminoskabju atvasinajumi
RU94046091A (ru) Полипептидные антагонисты бомбезина, фармацевтическая композиция и способ лечения
FI931826A0 (fi) Foerfarande foer framstaellning av en virussaeker, hoegt renad faktor viii
ES2104686T3 (es) Uso de una mezcla de peptidos y aminoacidos en la profilaxis o el tratamiento de la demencia.
DE3777367D1 (de) Hirudin-variante, deren verwendung und herstellung.
AU1496888A (en) Biologically active molecules
DE69400334D1 (de) Diaminsalze von clavulansäure
ATE308616T1 (de) Rantes mutanten und deren therapeutische verwendungen
FI891473A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
DE69018755D1 (de) Verfahren zur Herstellung von 3-(L-Pyroglutamyl)-L-thiazolidin-4-carbonsäure-Derivaten.
ATE130009T1 (de) Antitumor-aminosäuren und peptid-derivate von 1,4-bis((aminoalkyl und hydroxyaminoalkyl)amino>5,8- dihydroxyanthraquinonen.
ATE150018T1 (de) Imidazolyl-substituierte phenylessigsäureprolinamide
IT1230140B (it) Derivati della serina, loro processo di preparazione e impiego in terapia umana
BR0010499A (pt) Agentes endoparasiticidas
ATE101607T1 (de) Aroylharnstoffe.
BG101983A (en) Substituted phenylamidines, medicamentous forms containing them and mehtod for their preparation
CA2078000A1 (en) Neutrophil stimulating peptides
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
DE68916275D1 (de) 1-Carbacephalosporin-Antibiotika.
AU1691888A (en) Compound active in cardiovascular therapy
DE59106997D1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
ES2086395T3 (es) Fosfolipidos para el tratamiento de esclerosis multiple.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 452299

Country of ref document: ES